Cargando…

Effects of a new antioestrogen, idoxifene, on cisplatin- and doxorubicin-sensitive and -resistant human ovarian carcinoma cell lines.

Pyrrolidino-4-iodotamoxifen (idoxifene) is a new non-steroidal antioestrogen currently undergoing phase I clinical evaluation. Using idoxifene and tamoxifen and two additional analogues of tamoxifen (3-hydroxytamoxifen and 4-iodotamoxifen) and the imidazole-based calmodulin inhibitor, calmidazolium,...

Descripción completa

Detalles Bibliográficos
Autores principales:	Sharp, S. Y., Rowlands, M. G., Jarman, M., Kelland, L. R.
Formato:	Texto
Lenguaje:	English
Publicado:	Nature Publishing Group 1994
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2033360/ https://www.ncbi.nlm.nih.gov/pubmed/8080723

Ejemplares similares

Idoxifene is equipotent to tamoxifen in inhibiting mammary carcinogenesis but forms lower levels of hepatic DNA adducts.
por: Pace, P., et al.
Publicado: (1997)

Non-Steroidal Antioestrogens
por: Barnes, D.
Publicado: (1983)

The novel anti-oestrogen idoxifene inhibits the growth of human MCF-7 breast cancer xenografts and reduces the frequency of acquired anti-oestrogen resistance.
por: Johnston, S. R., et al.
Publicado: (1997)

First-line endocrine treatment of breast cancer: aromatase inhibitor or antioestrogen?
por: Wong, Z-W, et al.
Publicado: (2004)

Influence of the antioestrogen tamoxifen on normal breast tissue.
por: Walker, K. J., et al.
Publicado: (1991)

BCAR4 induces antioestrogen resistance but sensitises breast cancer to lapatinib
por: Godinho, M F E, et al.
Publicado: (2012)

Gene-specific repair of Pt/DNA lesions and induction of apoptosis by the oral platinum drug JM216 in three human ovarian carcinoma cell lines sensitive and resistant to cisplatin
por: O’Neill, C F, et al.
Publicado: (1999)

Lack of a role for MRP1 in platinum drug resistance in human ovarian cancer cell lines.
por: Sharp, S. Y., et al.
Publicado: (1998)

Preventive effects of antioestrogen on mammary and pituitary tumorigenesis in rats.
por: Sumi, C., et al.
Publicado: (1984)

BCL-2 family protein expression and platinum drug resistance in ovarian carcinoma
por: Beale, P J, et al.
Publicado: (2000)

Effects of the antioestrogen tamoxifen on the cell cycle kinetics of the human breast cancer cell line, MCF-7.
por: Lykkesfeldt, A. E., et al.
Publicado: (1984)

The timing of caffeic acid treatment with cisplatin determines sensitization or resistance of ovarian carcinoma cell lines
por: Sirota, R., et al.
Publicado: (2016)

APR-246 overcomes resistance to cisplatin and doxorubicin in ovarian cancer cells
por: Mohell, N, et al.
Publicado: (2015)

In vitro circumvention of cisplatin resistance by the novel sterically hindered platinum complex AMD473.
por: Holford, J., et al.
Publicado: (1998)

Reduced drug accumulation as a major mechanism of acquired resistance to cisplatin in a human ovarian carcinoma cell line: circumvention studies using novel platinum (II) and (IV) ammine/amine complexes.
por: Loh, S. Y., et al.
Publicado: (1992)

In vitro platinum drug chemosensitivity of human cervical squamous cell carcinoma cell lines with intrinsic and acquired resistance to cisplatin.
por: Mellish, K. J., et al.
Publicado: (1993)

Endocrinology and hormone therapy in breast cancer: Aromatase inhibitors versus antioestrogens
por: Howell, Anthony, et al.
Publicado: (2004)

Prospective study on gynaecological effects of two antioestrogens tamoxifen and toremifene in postmenopausal women
por: Marttunen, M B, et al.
Publicado: (2001)

Loss of oestrogen receptor alpha in long-term antioestrogen-resistant cells: reversal by a c-src inhibitor
por: Bensmail, A, et al.
Publicado: (2008)

Effect of polyunsaturated fatty acids on the drug sensitivity of human tumour cell lines resistant to either cisplatin or doxorubicin.
por: Plumb, J. A., et al.
Publicado: (1993)

Relationship between folate-binding protein expression and cisplatin sensitivity in ovarian carcinoma cell lines.
por: Ottone, F., et al.
Publicado: (1997)

Resistance to cisplatin does not affect sensitivity of human ovarian cancer cell lines to mifepristone cytotoxicity
por: Freeburg, Elizabeth M, et al.
Publicado: (2009)

The effect of clodronate and antioestrogens on bone loss associated with oestrogen withdrawal in postmenopausal women with breast cancer
por: Saarto, T, et al.
Publicado: (2001)

Mechanism of action of an orally administered platinum complex [ammine bis butyrato cyclohexylamine dichloroplatinum (IV) (JM221)] in intrinsically cisplatin-resistant human ovarian carcinoma in vitro.
por: McKeage, M. J., et al.
Publicado: (1994)

Clodronate improves bone mineral density in post-menopausal breast cancer patients treated with adjuvant antioestrogens.
por: Saarto, T., et al.
Publicado: (1997)

Gene expression and pathway analysis of ovarian cancer cells selected for resistance to cisplatin, paclitaxel, or doxorubicin
por: Sherman-Baust, Cheryl A, et al.
Publicado: (2011)

Hymenialdisine is Cytotoxic Against Cisplatin-Sensitive but Not Against Cisplatin-Resistant Cell Lines
por: Abdullah, Nada, et al.
Publicado: (2021)

In Vitro Effects of Oestrogens, Antioestrogens and SERMs on Pancreatic Solid Pseudopapillary Neoplasm-Derived Primary Cell Culture
por: Tognarini, Isabella, et al.
Publicado: (2010)

Carborane-Based ABCG2-Inhibitors Sensitize ABC-(Over)Expressing Cancer Cell Lines for Doxorubicin and Cisplatin
por: Paskas, Svetlana, et al.
Publicado: (2023)

Acquisition of platinum drug resistance and platinum cross resistance patterns in a panel of human ovarian carcinoma xenografts.
por: Jones, M., et al.
Publicado: (1993)

lncRNAs are novel biomarkers for differentiating between cisplatin-resistant and cisplatin-sensitive ovarian cancer
por: Li, Qing, et al.
Publicado: (2018)

Triggering necroptosis in cisplatin and IAP antagonist-resistant ovarian carcinoma
por: McCabe, K E, et al.
Publicado: (2014)

High-Definition DNA Methylation Profiles from Breast and Ovarian Carcinoma Cell Lines with Differing Doxorubicin Resistance
por: Boettcher, Michael, et al.
Publicado: (2010)

Cisplatin sensitivity and thermochemosensitisation in thermotolerant cDDP-sensitive and -resistant cell lines.
por: Hettinga, J. V., et al.
Publicado: (1995)

The Inhibitory Effect of Doxycycline on Cisplatin-Sensitive and -Resistant Epithelial Ovarian Cancer
por: Wu, Wei, et al.
Publicado: (2014)

Metformin combined with p38 MAPK inhibitor improves cisplatin sensitivity in cisplatin-resistant ovarian cancer
por: XIE, YA, et al.
Publicado: (2014)

Systemic chemotherapy with doxorubicin, cisplatin and capecitabine for metastatic hepatocellular carcinoma
por: Park, Se Hoon, et al.
Publicado: (2006)

Effects of 4-hydroxytamoxifen and a novel pure antioestrogen (ICI 182780) on the clonogenic growth of human breast cancer cells in vitro.
por: DeFriend, D. J., et al.
Publicado: (1994)

Cisplatin and Doxorubicin Induce Distinct Mechanisms of Ovarian Follicle Loss; Imatinib Provides Selective Protection Only against Cisplatin
por: Morgan, Stephanie, et al.
Publicado: (2013)

Transcriptome profile of OVCAR3 cisplatin-resistant ovarian cancer cell line
por: Sakhare, Shruti S, et al.
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_1op0tk5r6c72bou6nast0floh5